Abstract:

BACKGROUND: If endogenous stem cells levels were elevated in patients, and stem cells homing to a damaged site, and then self-repair ability was enhanced, which is accorded with reactive repair mechanism of self-damage, and can avoid immunologic rejection induced by allotransplantation.
OBJECTIVE: To investigate safety and availability on autologous stem cell stimulated by granulocyte colony-stimulating factor (G-CSF) orthotopic transplantation in treatment of young middle-age acute ischemic stroke by observing functional recovery and infarct area changes.
METHODS: A total of 40 cases of young middle-age acute cerebral infarction (middle cerebral artery territory) patients were divided into two groups randomly. In orthotopic transplantation group, 20 patients received subcutaneous G-CSF (15 μg/kg per day) injections for 5 days within 7-10 days following onset. The rest treatment was identical to the control group. In control group, patients were given conventional therapy of infarction. Before 10 days and 3 months after onset, National Institutes of Health Stroke Scale (NIHSS) and the Alberta stroke program CT score (ASPCTS) were performed.
RESULTS AND CONCLUSION: No patients developed severe adverse reaction during the treatment. NIHSS of treatment group after 3 months was lower and ASPCTS was higher significantly than the control group (P < 0.05). Results indicate that it was safe and effective for young middle-age patients with acute cerebral infarction to be treated by autologous stem cells stimulated by granulocyte colony-stimulating factor orthotopic transplantation. The treatment can decrease infarct size and improve the recovery of neurological function.